Immutep Reports A$68.9M Cash, Extends Runway to H1 2028 After TACTI-004 Wind-Down
IMMP sits 25% above its 52-week low of $0.293 on light trading volume (0.3× avg).
Summary
Immutep's Q4 FY26 report shows A$68.9 million in cash, extending runway to H1 2028 after repaying US$10 million to Dr. Reddy's and initiating cost cuts following the TACTI-004 futility outcome. The root cause analysis for the failed Phase III trial continues, with results expected in Q3 2026.
Key Events · Earnings and Guidance · IMMP
-
Cash Runway Extended to H1 2028
Cash, cash equivalents, and term deposits totaled A$68.87 million at 30 June 2026, with cost-reduction measures including headcount reductions and operating expense cuts extending runway into the first half of calendar 2028.
-
US$10M Repaid to Dr. Reddy's
Following the TACTI-004 discontinuation, Immutep repaid US$10 million (A$14.1 million) to licensing partner Dr. Reddy's, reducing unearned revenue; the remaining US$7.3 million was recognized as revenue for FY2026.
-
TACTI-004 Root Cause Analysis Ongoing
Investigation into the futility outcome continues, with preliminary data showing lower immune activation in the efti arm; additional results expected in Q3 CY2026.
-
IMP761 Phase I Data Positive
First-in-human study of LAG-3 agonist IMP761 met primary safety endpoint and showed significant pharmacodynamic activity, supporting further development in autoimmune diseases.
Analysis · IMMP · Life Sciences
Immutep's quarterly report reveals a critical financial pivot after the Phase III TACTI-004 trial was halted for futility. The company repaid US$10 million to partner Dr. Reddy's, leaving A$68.9 million in cash — enough to fund operations into the first half of 2028 after implementing cost cuts including headcount reductions. While the cash position removes near-term liquidity fears, the root cause analysis of the failed lung cancer trial is ongoing, with results expected in Q3 2026. Positive updates from IMP761 in autoimmune disease and EFTISARC-NEO in sarcoma provide some pipeline offset, but the core efti program faces significant uncertainty. The voluntary dismissal of a securities class action removes a legal overhang.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 37.4% of the 952 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMMP was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.6M. The 52-week trading range was $0.29 to $3.53. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.